Payment for oncolytics in the United States: a history of buy and bill and proposals for reform.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed.

1. Cost-effectiveness of Enasidenib versus conventional care for older patients withLeukemia & lymphoma · 2025
   Trial
2. Private equity acquisitions and cancer care: nothing to see here? Not so fast.Journal of the National Cancer Institute · 2026
   Article
3. Stakeholder perspectives on the sustainability of the United States biosimilars market.Journal of managed care & specialty pharmacy · 2024
   Article
4. Commercial Versus Medicaid Insurance and Use of High-Priced Anticancer Treatments.The oncologist · 2024
   Article
5. Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients withLeukemia & lymphoma · 2023
   Article
6. Real-World Use of Bone-Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer.Journal of the National Cancer Institute · 2022
   Article
7. Greater uptake, an alternative reimbursement methodology needed to realize cost-saving potential of oncology biosimilars in the United States.Journal of managed care & specialty pharmacy · 2021
   Article
8. Trends and Disparities in Asthma Biologic Use in the United States.The journal of allergy and clinical immunology. In practice · 2020
   Article
9. Drug Treatment Value in a Changing Oncology Landscape: A Literature and Provider Perspective.Journal of managed care & specialty pharmacy · 2019
   Review
10. Biosimilars: Considerations for Payers.P & T : a peer-reviewed journal for formulary management · 2019
    Article
11. Diffusion of Bevacizumab Across Oncology Practices: An Observational Study.Medical care · 2018
    Observational
12. Biosimilars: Opportunities to Promote Optimization Through Payer and Provider Collaboration.Journal of managed care & specialty pharmacy · 2016
    Article
13. Are Small Reimbursement Changes Enough to Change Cancer Care? Reimbursement Variation in Prostate Cancer Treatment.Journal of oncology practice · 2016
    Article
14. Reform of the Buy-and-Bill System for Outpatient Chemotherapy Care Is Inevitable: Perspectives from an Economist, a Realpolitik, and an Oncologist.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2015
    Article

Corrections and comments

• Commented on by
  Oncology payment reform and drug reimbursement in the proper perspective.2015
• Commented on by
  Reply to M. Thompson et Al.2015

Authors and funding

7 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as